Brief: Eiger Biopharmaceuticals Files For Voluntary Chapter 11 Protection

Eiger Biopharmaceuticals

01/04/2024 16:15

April 1 (Reuters) - Eiger BioPharmaceuticals Inc
 EIGR.O :
    * EIGER BIOPHARMACEUTICALS FILES FOR VOLUNTARY CHAPTER 11
PROTECTION
    * EIGER BIOPHARMACEUTICALS INC - PATIENT ACCESS TO ZOKINVY®
TO
CONTINUE UNINTERRUPTED
    * EIGER BIOPHARMACEUTICALS INC: PATIENT ACCESS TO ZOKINVY(®)
TO
CONTINUE UNINTERRUPTED
    * EIGER BIOPHARMACEUTICALS INC - PATIENT ACCESS TO
ZOKINVY(®) TO
CONTINUE UNINTERRUPTED
    * EIGER BIOPHARMACEUTICALS INC: UNDER TERMS OF "STALKING
HORSE"
AGREEMENT, SUBJECT TO COURT APPROVAL, SENTYNL THERAPEUTICS WILL
PAY UP TO $26.0 MILLION
    * EIGER BIOPHARMACEUTICALS -  FILED CUSTOMARY "FIRST DAY"
MOTIONS
WITH COURT REQUESTING RELIEF DESIGNED TO ENABLE EIGER TO
TRANSITION INTO CHAPTER 11
    * EIGER BIOPHARMACEUTICALS INC: ANNOUNCES "STALKING HORSE"
AGREEMENT FOR SALE OF ZOKINVY(®) (LONAFARNIB)
    * EIGER BIOPHARMACEUTICALS - INTENDS TO SELL SUBSTANTIALLY
ALL OF
ITS ASSETS DURING BANKRUPTCY CASE, TO FACILITATE ORDERLY WIND
DOWN OF OPERATIONS

Source text for Eikon:  ID:nGNX83j6V 
Further company coverage:  EIGR.O 

 ((Reuters.Briefs@thomsonreuters.com;))